During the treatment of glioma, TMZ could be selected according to the expression levels of GSDMD, which was obviously upregulated in GBM, thereby increasing the sensitivity to chemotherapeutic drugs and reducing drug resistance. Here, GSDMD is linked to central nervous system cancer.